Table 1. Baseline characteristics among treated California acute leukemia patients, 2009–2014.
| AML | ALL | |||
|---|---|---|---|---|
| Variables | N = 3,252 | % | N = 1,820 | % |
| Leukemia subtype | ||||
| AML-APL | 406 | 12.5% | – | – |
| ALL-T cell | – | – | 166 | 9.1% |
| ALL-B cell | – | – | 1,650 | 90.7% |
| Incident UE DVT | ||||
| Yes | 234 | 7.2% | 114 | 6.3% |
| No | 3,018 | 92.8% | 1,706 | 93.7% |
| Subsequent PE or LE DVT | ||||
| PE Only | 59 | 1.8% | 40 | 2.2% |
| PE + DVT | 20 | 0.6% | 12 | 0.7% |
| DVT-proximal only | 40 | 1.2% | 27 | 1.5% |
| DVT-distal only | 24 | 0.7% | 12 | 0.7% |
| DVT-lower extremity, NOS only | 2 | 0.1% | 2 | 0.1% |
| Gender | ||||
| Male | 1,805 | 55.5% | 1,077 | 59.2% |
| Female | 1,447 | 44.5% | 743 | 40.8% |
| Race/Ethnicity | ||||
| Non-Hispanic White | 1,755 | 54.0% | 531 | 29.2% |
| African American | 192 | 5.9% | 87 | 4.8% |
| Hispanic | 819 | 25.2% | 1,018 | 55.9% |
| Asian/Pacific Islander | 453 | 13.9% | 169 | 9.3% |
| Other/Unknown | 33 | 1.0% | 15 | 0.8% |
| Age at cancer diagnosis | ||||
| <18 | 161 | 5.0% | 770 | 42.3% |
| 18–39 | 521 | 16.0% | 449 | 24.7% |
| 40–59 | 977 | 30.0% | 372 | 20.5% |
| 60–69 | 764 | 23.5% | 146 | 8.0% |
| ≥70 | 829 | 25.4% | 83 | 4.6% |
| HSCT | ||||
| Yes | 732 | 22.5% | 335 | 18.4% |
| No | 2,520 | 77.5% | 1,485 | 81.6% |
| Comorbidities (within 2 y prior) | ||||
| Not available | 897 | 27.6% | 397 | 21.8% |
| 0 | 204 | 6.3% | 301 | 16.5% |
| 1–2 | 869 | 26.7% | 668 | 36.7% |
| ≥3 | 1,282 | 39.4% | 454 | 24.9% |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; HSCT, hematopoietic stem cell transplantation; LE DVT, lower extremity deep vein thrombosis; NOS, not otherwise specified; PE, pulmonary embolism; UE DVT, upper extremity deep vein thrombosis.